Sorinvia Benigno Crespi 17
Milano 20159
Italy
[t] 0039-02-69969711-509
|
|
The Sorin Group is a world leader in the development of medical technologies for cardiac surgery, offers innovative therapies for cardiac rhythm dysfunctions, interventional cardiology and the treatment of chronic kidney diseases.The Sorin Group features the following brands: Dideco, CarboMedics, COBE Cardiovascular, Stockert, Mitroflow, ELA Medical, Sorin Biomedica, Bellco and Bellco-Soludia. At the Sorin Group 4,500 employees serve over 5,000 public and private treatment centres in more than 80 countries. |
| |
|
Sorin Group acquires Gish Biomedical from Ventizz Capital Partners, a private equity group focused on technology-oriented companies. |
10 June 2010 |
| |
|
Sorin Group enters into a distribution agreement with CardioMedical, making Sorin Group, CardioMedical’s selected partner for the entire Cardio Vision MIS Portfolio which is a comprehensive catalogue of minimally invasive cardiac surgery instruments and accessories. |
05 May 2010 |
| |
|
The US Food and Drug Administration gives clearance for Sorin’s newest generation C5 Heart-Lung Machine (HLM). |
22 February 2010 |
| |
|
Sorin Group receives US FDA approval and completes first implant of its next-generation of cardiac resynchronization therapy defibrillator (CRT-D), Paradym CRT Model 8750. |
09 February 2010 |
| |
|
Sorin Group reports the first inclusion of a patient in the Clepsydra clinical trial which will investigate the sensitivity to changes in heart failure status of PhD, a diagnostic feature using the dual sensor technology of minute ventilation and accelerometer to monitor patient’s breathing and activity levels every day. |
04 December 2009 |
| |
|
Orange Business Services and Sorin Group are named ‘Best Change-Maker’ at this year’s annual World Communication Awards (WCA) for their innovative work in the development of a remote monitoring solution for cardiac patients. |
02 December 2009 |
| |
|
Sorin Group receives the Health Canada Therapeutic Products Directorate (TPD) approval to market the REPLY family of dual and single chamber rate adaptive pacemakers. |
10 July 2009 |
| |
|
Japan’s Ministry of Health, Labor and Welfare (MHLW) gives approval to market the Facil and Reply families of dual and single chamber rate responsive pacemakers. |
06 July 2009 |
| |
|
Sorin Group delivers its 1000th S5 Heart-Lung Machine with a contract to supply the Mount Sinai Medical Center, one of the world’s leading centres for cardiovascular medicine, based in New York, USA. |
29 June 2009 |
| |
|
Sorin Group announces the release and first implant of its new generation Paradym DR 8550 dual chamber implantable cardioverter-defibrillator (ICD). |
25 June 2009 |
| |
|
Sorin Group is entering into a long-term exclusive distribution agreement with Japan Lifeline (JLL), a leading distributor of medical devices in Japan. |
20 April 2009 |
| |
|
Sorin Group receives CE mark certification releases the ESPRIT pacemaker family to the market in Europe. |
07 April 2009 |
| |
|
Sorin Group together with Orange Business Services, the leading global communications solutions integrator, are planning to develop and service a remote monitoring solution for patients implanted with cardiac rhythm management (CRM) devices. |
20 March 2009 |
| |
|
Sorin Group has enrolled the first three patients in a clinical trial aimed at obtaining European market approval for the company’s ‘Perceval S’ Sutureless Aortic Heart Valve. |
26 February 2009 |
| |
|
Sorin Group has acquired the Clearglide endoscopic vessel harvesting product line of Datascope. Endoscopic vessel harvesting (‘EVH’) devices enable less-invasive harvesting of vessels for use in coronary artery bypass grafting. |
13 February 2009 |
| |
|
Sorin Group has completed the divestment of its Renal Care Business to an investment consortium led by Argos Soditic, an independent European private equity firm, and MPS Venture SGR, on behalf of the closed-end fund ‘Emilia Venture’. |
02 January 2009 |
| |
|
Sorin Group has received Japanese approval for its Isoline defibrillation leads which are now released to the Japanese market. |
12 December 2008 |
| |
|
Sorin Group has entered into a binding asset purchase agreement to purchase the Clearglide endoscopic vessel harvesting product range from Datascope. |
28 November 2008 |
| |
|
Sorin Group has released its new-generation Paradym CRT 8750 cardiac resynchronization therapy defibrillator (CRT-D) and completed the device's first implant. |
27 November 2008 |
| |
|
Sorin Group has signed an agreement to apply Sphere Medical’s proprietary microsensor technology in the field of cardiopulmonary bypass. |
19 November 2008 |
| |
|
Sorin Group has received an offer for the acquisition of its renal care business and the group has granted exclusivity to an investment consortium led by Argos Soditic, an independent European private equity firm, and MPS Venture SGR, for the purpose of finalising negotiations. |
13 October 2008 |
| |
|
Sorin Group has announced the first patient enrolment in the e-Optima registry which is designed to assess the clinical performance of the Sorin Group Optima Drug-Eluting Stent (DES) Carbostent in the treatment of real-world patients in routine clinical practice. |
23 September 2008 |
| |
|
A report detailing 21-year durability data of Sorin’s Mitroflow Aortic Pericardial Heart Valve has been published in the September issue of the Journal Of Thoracic And Cardiovascular Surgery. |
17 September 2008 |
| |
|
The Sorin Group has announced the first successful uses in the USA of the company's newest paediatric devices for cardiovascular surgery. |
15 September 2008 |
| |
|
The Sorin Group has received US Food and Drug Administration’s approval to market the Reply family of dual and single chamber pacemakers. |
07 August 2008 |
| |
|
Sorin Group has divested its peripheral stent business to Datascope, which has become the new owner of the entire Sorin peripheral vascular stent product business worldwide. |
12 June 2008 |
| |
|
The Sorin Group and Greatbatch is to collaborate to enable Greatbatch's eM-able technology to be use in the Sorin Group's future cardiac rhythm management (CRM) systems. |
20 May 2008 |
| |
|
The Sorin Group has received US Food and Drug Administration's approval to market the CRT model of the company’s Ovatio family. |
19 May 2008 |
| |
|
Sorin Group Cardiac Rhythm Management has completed the first implant in a clinical trial of its new-generation Paradym 8770 sonR cardiac resynchronization therapy defibrillator (CRT-D). |
01 May 2008 |
| |
|
The Sorin Group has received the Japanese Pharmaceutical and Medical Devices Agency's (PMDA) approval to market its Stockert S5 Heart-Lung Machine in Japan. |
24 April 2008 |
| |
|
ELA Medical, a Sorin Group company, has received the US Food and Drug Administration's approval to market the Isoline range of defibrillation leads. |
14 March 2008 |
| |
|
The Sorin Group plans to support a clinical trial of the Sorin MEMO 3D Annuloplasty Ring for mitral valve repair, which will evaluate the effectiveness and clinical outcomes of MEMO 3D when used to repair a diseased or dysfunctional mitral valve. |
18 February 2008 |
| |
|
ELA Medical, a Sorin Group company, has announced the first US enrollment in the Option study (Optimal Anti-tachycardia Therapy in ICD Patients without Pacing Indications) by Dan Dan, MD, electrophysiologist and co-director of Cardiovascular Research of the Fuqua Heart Center at Piedmont Hospital, Atlanta, Georgia, USA. |
06 December 2007 |
| |
|
The Sorin Group has completed the first commercial implant of the Mitroflow Aortic Pericardial Heart Valve in the USA, performed by the Cardiovascular Surgery Division at Mayo Clinic in Rochester, Minnesota, USA. |
06 December 2007 |
| |
|
The Sorin Group has received the US Food and Drug Administration's approval to market the company’s Mitroflow Aortic Pericardial Heart Valve in the USA. |
26 October 2007 |
| |
|
ELA Medical, a Sorin Group company, has completed the first US implant in the investigational trial of the Ovatio CRT, Cardiac Resynchronization Therapy Defibrillator, Model 6750. |
22 October 2007 |
| |
|
The Sorin Group has received the US Food and Drug Administration's authorisation for marketing its Memo 3D Semirigid Annuloplasty Ring in the USA. |
25 September 2007 |
| |
|
The single chamber and dual chamber models Ovatio VR 6250 and DR 6550 ICD have received regulatory and reimbursement approval from the Ministry of Health, Labor and Welfare. |
31 August 2007 |
| |
|
Sorin and Japan Lifeline have signed a ten year partnership agreement that will see JLL distribute Sorin's cardiac rhythm management (CRM) devices throughout Japan. |
28 June 2007 |
| |
| |
